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Enhanced sensitivity to glucocorticoids in cytarabine-
resistant AML
D Malani1, A Murumägi1, B Yadav1, M Kontro2, S Eldfors1, A Kumar1, R Karjalainen1, MM Majumder1, P Ojamies1, T Pemovska1,
K Wennerberg1, C Heckman1, K Porkka2, M Wolf1, T Aittokallio1,3 and O Kallioniemi1,4
We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (AML) by generating eight
resistant variants from MOLM-13 and SHI-1 AML cell lines by long-term drug treatment. These cells were compared with 66
ex vivo chemorefractory samples from cytarabine-treated AML patients. The models and patient cells were subjected to
genomic and transcriptomic proﬁling and high-throughput testing with 250 emerging and clinical oncology compounds.
Genomic proﬁling uncovered deletion of the deoxycytidine kinase (DCK) gene in both MOLM-13- and SHI-1-derived cytarabine-
resistant variants and in an AML patient sample. Cytarabine-resistant SHI-1 variants and a subset of chemorefractory AML
patient samples showed increased sensitivity to glucocorticoids that are often used in treatment of lymphoid leukemia but not
AML. Paired samples taken from AML patients before treatment and at relapse also showed acquisition of glucocorticoid
sensitivity. Enhanced glucocorticoid sensitivity was only seen in AML patient samples that were negative for the FLT3 mutation
(P = 0.0006). Our study shows that development of cytarabine resistance is associated with increased sensitivity to
glucocorticoids in a subset of AML, suggesting a new therapeutic strategy that should be explored in a clinical trial of
chemorefractory AML patients carrying wild-type FLT3.
Leukemia (2017) 31, 1187–1195; doi:10.1038/leu.2016.314
INTRODUCTION
Cytarabine (Ara-C or 1-beta-D-arabinofuranosylcytosine) has
remained the cornerstone of therapy for adult acute myeloid
leukemia (AML) patients for decades.1,2 Induction therapy
comprised of cytarabine in combination with anthracyclines, leads
to responses in 60–70% of adult AML patients.3,4 However, relapse
due to acquired resistance is common and the overall long-term
survival of adult AML patients is o40%.5,6 Therefore, better
insights are needed about potential therapeutic regimens to
either prevent resistance from arising or to treat patients resistant
to cytarabine.2
There are several mechanisms playing a role in cytarabine
resistance in different types of leukemia. Mutation, deletion and
reduced gene and protein expression of deoxycytidine kinase
(DCK) have been reported in AML and ALL cell lines and clinical
samples.7–11 In addition, genetic aberrations in the SLC29A1, CDA
and NT5C2 genes have been associated with clinical resistance as
well as acquired and/or intrinsic in vitro resistance in AML.12–14
Deregulation of apoptosis, such as BCL-2 overexpression, has also
shown to be responsible for cytarabine resistance in both AML cell
lines and clinical samples.15,16 Upregulation of NK cell-activating
receptor NKG2D gene was reported to be associated with
cytarabine resistance in T-cell lymphoid leukemia cell lines.17
Variation in the function of multi-drug resistance (MDR) genes
often causes resistance to nucleoside analog drugs.18 Negoro
et al.19 characterized ﬁve cytarabine-resistant cell lines from
different blood cell lineages and reported that differential
expression of eight genes associated with cytarabine resistance.
These studies of resistance mechanisms have not yet led to the
development of therapeutic strategies to prevent or overcome
resistance.
It is important to identify drugs able to overcome cytarabine
resistance. A clinical trial showed that clofarabine induces
cytarabine-mediated cytotoxicity by chemical inhibition of ribo-
nucleotide reductase in chemorefractory AML patients.20 Other
approaches reported to overcome cytarabine resistance include
(i) targeting sonic hedgehog pathway gene GLI1,21,22 (ii) treatment
with BH3 mimetics23 or (iii) BCL-2 inhibitor YC137 in combination
with guanine arabinoside.24 These studies have highlighted the
strategies to counter cytarabine resistance but their clinical
translation has not yet been achieved.
Here we hypothesized that generation of drug resistance
to a chemotherapeutic agent is likely to increase vulnerability
to other drugs. We ﬁrst generated a series of cytarabine-
resistant variants from the MOLM-13 and SHI-1 AML cell
lines. To identify drugs effective against the resistance,
the cytarabine-resistant variants were subjected to high-
throughput drug sensitivity and resistance testing (DSRT) with
250 oncology drugs. The drug-resistant cells were also
characterized for gene expression, copy number variation and
mutations. The molecular and functional data from these
in vitro models were compared with data from ex vivo analysis
of 66 relapsed and refractory AML patient samples, including
paired samples from patients taken before and after che-
motherapy, including cytarabine.
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MATERIALS AND METHODS
Development of cytarabine-resistant AML cell lines
Cytosine β-D-arabinofuranoside (cytarabine, Ara-C, Sigma-Aldrich, St. Louise,
MO, USA) was dissolved in DMSO. MOLM-13 and SHI-1 AML cell lines
were purchased from the DSMZ (Braunschweig, Germany). MOLM-13 and
SHI-1 cells were cultured DSMZ-speciﬁed media. Both AML cell lines were
treated with cytarabine and doses were doubled when the AML cells
started to proliferate at an equal rate as the untreated parental cells. Cell
line variants resistant to 160, 320, 640 and 1280 nM concentrations were
named as M 160 Ara-C, M 320 Ara-C, M 640 Ara-C, M 1280 Ara-C for
MOLM-13 and S 160 Ara-C, S 320 Ara-C, S 640 Ara-C, S 1280 Ara-C for SHI-1.
The authenticity of each cell type was tested StemElite ID (Promega,
Madison, WI, USA) kit.
Patient samples
Peripheral blood or bone marrow aspirates (n=66) were collected from 48
individual AML patients and 15 healthy donors. Skin biopsies were used as
a germline control. Informed consent was obtained from all the patients
and the samples were collected using approved study protocols (Helsinki
Ethical Committee 239/13/03/00/2010 and 303/13/03/01/2011). Paired
samples were taken from AML patients before and after relapse under
cytarabine therapy. Clinical details of AML patients are given in Table 1.
Drug sensitivity and resistance testing (DSRT)
Brieﬂy, DSRT was performed with MOLM-13 and SHI-1 parental and
respective cytarabine-resistant cells with 250 active chemical compounds
(Supplementary Table 1). DSRT assay details are given in Supplementary
methods. Drug efﬁcacy was quantiﬁed with a drug sensitivity score (DSS),
which is modiﬁed area-under-the-curve measurement.25 The DSS of
cytarabine-resistant cell lines and patient samples 3443_3 and 3443_6
are provided in Supplementary Table 1. Selective DSS was calculated by
subtracting from the patient DSS, the average of healthy control DSS. The
selective DSS of glucocorticoids—dexamethasone, methylprednisolone
and prednisolone are listed for all patient samples in Supplementary
Table 2.
Molecular proﬁling and western blot analysis
We analyzed gene expression, mutation and copy number changes in AML
cell lines. The methodology and data analysis pipeline details are described
in Supplementary methods. Brieﬂy, copy number and mutation data were
analyzed as described previously.26–28 Exome sequencing were performed
for 29 samples and the data were analyzed as described earlier.26 Western
blot analysis is described in Supplementary Methods.
Target addiction scoring
Target addiction score (TAS) is a quantitative measure of the functional
sensitivity of cell line variants to the therapeutic targets, calculated on
the basis of estimated level of addiction of cells to a target protein.29 The
TAS algorithm integrates DSS proﬁles with global compound–target
interaction networks. All the on and off targets of the 202 targeted
compounds were collected and integrated using the Kinase inhibitor
BioActivity (KiBA) model.30 To select targets of the compounds, we
applied the KiBA cutoffp 3 for 181 compounds and the KiBA cutoffp 4
for the rest of the 21 compounds. For a given target t, TAS was
computed as an average of the DSS over those n inhibitors that target
the protein t:
TASt ¼
Xn
i¼1
DSSi
n
TAS calculation generated target addiction proﬁles of the individual cell
types including both parental and cytarabine-resistant cells.
Statistical analyses
The dose response percent inhibition values were ﬁtted with non-linear
regression and four parameter logistic curve. DSS and TAS were calculated
as previously described.25,29 TAS and gene expression were compared
using Spearman rank test. The Student’s t-test, Mann–Whitney U-test and
correlation analyses were performed using Prism software version 6
(GraphPad Prism, San Diego, CA, USA). Statistical signiﬁcance was
considered at two-tailed Po 0.05.
RESULTS
Development of cytarabine-resistant MOLM-13 and SHI-1 variants
A schematic overview of this study is presented in Figure 1a.
First, we generated cytarabine-resistant AML cell line models
from SHI-1 and MOLM-13 followed by systematic molecular
proﬁling and drug testing. High-throughput drug testing data
showed drugs with co-resistance and novel vulnerability
patterns in cytarabine-resistant cells compared with parental
cells. These in vitro ﬁndings were compared with ex vivo
cytarabine-treated relapsed and refractory AML patient samples
to identify the clinical relevance of results observed in
cytarabine resistance cells.
The MOLM-13 cell line was selected as cells harbor an internal
tandem duplication (ITD) in FLT3, a most common aberration in
adult AML patients.31 The SHI-1 cell line carries a hot spot
Table 1. Clinical characteristics of adult AML patients
Patient
identiﬁer
Diagnosis Sample
number
Sample type Age Disease status Time
from
dignosis
(months)
Cytogenetics Previous therapies for AML
1145 Therapy-related AML 1145_2 Bone marrow 41 Diagnosis 0 Hyperdipo 43, t(5; 6),
t(7; 9), − 19, − 20, −Y
–
1145_3 Bone marrow 43 Relapse 15 Cytarabine, azacitidine,
allogenic HSCT
1064 Therapy-related AML 1064_1 Bone marrow 37 Diagnosis 0 abn(3) –
1064_3 Bone marrow 40 First relapse 30 abn(3) Cytarabine-antracycline,
HSCT (MUD)
3443 AML without
maturation
3443_3 Bone marrow 21 Resistant disease 1 del 17p, − 2 (both), − 17
(both), − 5, − 6, − 7, − 11, − 12,
− 18, − 22, +13,+21, 6–8
marker chromosomes
Cytarabine-antracycline
3443_6 Bone marrow 22 Resistant disease 4 As above, 8–12 marker
chromosomes
Cytarabine-antracycline,
ruxolitinib-everolimus,
clofarabine-cytarabine
Abbreviations: abn(3), abnormal chromosome 3; AML, acute myeloid leukemia; del, deletion; HSCT, hematopoietic stem cell transplantation; MUD, matched
unrelated donor.
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mutation in the KRAS and MLL-AF6 rearrangement, representing
another established subset of AML patients.32 MOLM-13 and SHI-1
cytarabine variants, 160 Ara-C, 320 Ara-C, 640 Ara-C and 1280
Ara-C, generated in 8 months depicted stepwise development
of resistance (Figure 1b and c). The drug-resistant variants were
conﬁrmed to represent the parental MOLM-13 or SHI-1 cell line
by genetic authentication. The growth rates of the cytarabine-
resistant variants were measured and found to be similar to the
parental cells in MOLM-13 and SHI-1 cells (Supplementary Figure
1A and B). In addition, we cultured M 1280 Ara-C cells without
cytarabine for 3 weeks, which did not result in the loss of
cytarabine resistance (Supplementary Figure 1C). This indicates
that cytarabine resistance was not reversible and thereby
unlikely to be due to transient cell signaling changes or
epigenetic modiﬁcations.
Copy number and gene expression proﬁling showed deletion and
downregulation of DCK in cytarabine-resistant cells
To identify copy number changes and mutations associated with
cytarabine resistance, MOLM-13 and SHI-1 1280 Ara-C cells were
subjected to whole-exome sequencing and compared with
respective parental cells. Drug-resistant SHI-1 cells displayed copy
number aberrations involving larger genomic regions as com-
pared with the corresponding MOLM-13 cells (Supplementary
Tables 3 and 4). However, we found shared copy number
variations speciﬁc to cytarabine resistance in both model systems
parental cells 160 Ara-C 320 Ara-C 640 Ara-C 1280 Ara-C
Long term (8 months) cytarabine treatment
Molecular profiling
Mutation and copy
number analysis
Gene expression
analysis
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Figure 1. Overview of the study design. (a) Schematic diagram illustrating generation of cytarabine-resistant cell line variants (upper panel)
and collection of bone marrow mononuclear cells before and after cytarabine treatment in AML patients (middle panel). Subsequently,
molecular proﬁling, high-throughput drug testing and bioinformatics data integration from cytarabine-resistant cell line variants and patient
samples were studied (lower panel) to clinically validate the results. (b, c) The sensitivity of MOLM-13 and SHI-1 parental and cytarabine-
resistant variants to cytarabine was tested with cell viability assay after 72 h incubation with drug concentrations ranging from 1 to 10 000 nM.
The bars represent mean ± s.d.
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(Figure 2a), such as the copy number loss at 4q13.3 at the location
of the DCK gene, previously reported to be responsible for
cytarabine resistance.14
We also analyzed copy number changes and mutations from
all available serial samples of AML patients. Serial samples taken
from patient 3443 were designated as 3443_3 and 3443_6
(Table 1). 3443_6 sample, taken after two cycles of in vivo
cytarabine-based treatment, showed homozygous deletion of
DCK gene. Interestingly, the deletion breakpoints for the
DCK gene in 3443_6 cells were at the same genetic location as
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Figure 2. Molecular proﬁling of cytarabine-resistant cells revealed DCK deletion. (a) Genome-wide copy number analysis by exome sequencing
was performed with 1280 Ara-C-resistant MOLM-13 and SHI-1 variants using respective parental cells as controls. Individual chromosomes are
presented on the x axis and copy number ratios on the y axis. (b) Copy number analysis of AML patient samples 3443_3 (obtained before
cytarabine treatment) and 3443_6 (obtained after cytarabine treatment) showed acquisition of homozygous deletion of DCK gene acquired
after the patient was treated with two cycles of cytarabine-based therapy. (c, d) Microarray-based expression of DCK in MOLM-13 and SHI-1
parental and cytarabine-resistant variants.
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in M 1280 Ara-C (Figure 2b). Moreover, gene expression
data conﬁrmed downregulation of DCK gene in all four
cytarabine-resistant variants from MOLM-13 and SHI-1 com-
pared with respective parental cells (Figures 2c and d;
Supplementary Table 5).
Loss of DCK function correlated with co-resistance to nucleoside
analogs in cytarabine-resistant cells
MOLM-13 and SHI-1 parental and cytarabine-resistant variants
were subjected to DSRT. The comparison of individual cytarabine-
resistant variants with their respective parental cells showed
consistent patterns of drug sensitivity and resistance (Figure 3a).
The nucleoside analogs tested were clofarabine, cladribine and
gemcitabine. Co-resistance patterns were conﬁrmed by a sig-
niﬁcant correlation between cytarabine and individual nucleoside
analogs in both MOLM-13 and SHI-1 variants (Figures 3b and c).
Similarly, DSRT data of AML patient sample 3443_6 with the DCK
deletion showed complete resistance to cytarabine along with
gemcitabine, cladribine and clofarabine as compared with an
earlier sample from the same patient (3443_3), which had no DCK
deletion and showed moderate cytarabine sensitivity (Figure 3d).
Systematic drug testing of the cytarabine-resistant cell line variants
indicated acquisition of glucocorticoid sensitivity
Interestingly, DSRT of all cytarabine-resistant SHI-1 cell line variants
revealed systematic increase in sensitivity to glucocorticoids
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Figure 3. Nucleoside analogs showed stepwise co-resistance to cytarabine in AML cell lines and in an AML patient sample. (a) DSS for 250
drugs from individual MOLM-13 (Ai-Aiv) and SHI-1 (Av-Aviii) cytarabine-resistant variants were correlated with the corresponding parental
cells to depict differential drug sensitivities and resistance patterns. DSS illustrates ex vivo sensitivity to the compound (high DSS meaning
high sensitivity). Drugs showing co-resistance represented in black dots and vulnerabilities in black triangles in cytarabine-resistant variants
compared with parental cells. (b, c) Cytarabine-resistant MOLM-13 and SHI-1 variants demonstrated consistent co-resistance pattern to
nucleoside analogs by decreasing DSS values. Pearson correlation analysis was performed between cytarabine and individual nucleoside
analogs; r indicated correlation values with Po0.05. (d) Comparison of DSS between AML patient samples 3443_3 and 3443_6 showed
distinct pattern of co-resistance for nucleoside analogs, including cytarabine, gemcitabine, clofarabine and cladribine, shown in blue.
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(Figure 4a). The glucocorticoids used in the drug testing included
dexamethasone, methylprednisolone and prednisolone, which
showed minimal efﬁcacy in SHI-1 parental cells. The S 160 Ara-C, S
320 Ara-C, S 640 Ara-C and S 1280 Ara-C-resistant variants were
increasingly sensitive to methylprednisolone, prednisolone and
dexamethasone. The Pearson correlation between cytarabine
and individual glucocorticoids (dexamethasone r = − 0.98,
methylprednisolone r = − 0.92 and prednisolone r = − 0.96)
revealed a statistically signiﬁcant (Po0.05) inverse relationship
between acquired cytarabine resistance and glucocorticoid
sensitivity (Figure 4b). The increasing glucocorticoid sensitivity
was conﬁrmed by repeating drug testing with a wide
concentration range (nine doses between 1 and 10 000 nM)
of glucocorticoids in cytarabine-resistant SHI-1 variants
(Figures 4c–e). However, glucocorticoid sensitivity was not
observed in MOLM-13 parental or cytarabine-resistant variants
(Supplementary Figure 2A).
NR3C1 (glucocorticoid receptor) upregulation is associated with
glucocorticoid sensitivity in cytarabine-resistant SHI-1 variants
To deﬁne the potential mechanisms associated with glucocorti-
coid sensitivity, a network-based model was applied to reveal
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Figure 4. Cytarabine-resistant SHI-1 cells exhibited enhanced sensitivity to glucocorticoids and upregulation of NR3C1. (a) SHI-1 parental and
cytarabine-resistant variants showing sensitivity to three glucocorticoids—dexamethasone, methylprednisolone and prednisolone.
(b) Correlation was calculated between DSS of cytarabine and individual glucocorticoids in SHI-1 cytarabine-resistant variants; r indicates
Pearson correlation with Po0.05. (c, d, e) A targeted small-scale drug testing experiment was performed in SHI-1 parental and cytarabine-
resistant variants to validate the high-throughput DSRT data on glucocorticoid sensitivity. Glucocorticoids were tested with nine doses in
triplicates with same parameters as in the DSRT assay. The bars represent mean ± s.d. (f) TAS was calculated and correlated with gene
expression proﬁles in SHI-1 parental and cytarabine-resistant variants; r indicates Spearman correlation, where P= 0.02. (g) NR3C1 protein
expression was analyzed using western blotting in SHI-1 parental and cytarabine-resistant cells. The integrated intensities of protein bands
were quantiﬁed by Odyssey software and normalized against GAPDH.
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candidate molecular targets behind the observed drug response
proﬁles in the cytarabine-resistant variants.29 Polypharmacological
on- and off-target effects were modeled using TAS for each target
protein on the basis of the DSRT data. Correlation between TAS
and gene expression showed consistent increase in Nuclear
Receptor Subfamily 3, Group C, Member 1 (NR3C1; Figure 4f). The
integrated analysis identiﬁed NR3C1 as one of the top positively
correlated genes (r= 0.93, P= 0.02) in SHI-1 cells (Supplementary
Table 6). NR3C1 protein expression increased substantially
compared gene expression with acquired cytarabine resistance
(Figure 4g) and increased glucocorticoid sensitivity in SHI-1 cells
(Supplementary Figure 3). However, NR3C1 gene or protein
expression, along with glucocorticoid sensitivity, did not increase
in MOLM-13 cytarabine-resistant variants compared with the
parental cells (Supplementary Figure 2B and C).
DSRT of clinical samples suggested enhanced glucocorticoid efﬁcacy
in relapsed/refractory AML
We assessed ex vivo drug sensitivity data available for paired
diagnostic and relapsed samples from two patients 1064 and
1145. We compared drug responses for all three glucocorticoids—
dexamethasone, methylprednisolone and prednisolone between
these paired samples in both patients. We observed signiﬁcant
increase in efﬁcacy of glucocorticoids in relapsed samples
compared with their respective diagnostic samples in 1064
(P= 0.009) and 1145 (P= 0.013; Figures 5a and b). Cytarabine
was included in the induction therapy for the patients, along with
other chemotherapeutics (Table 1). However, it is challenging to
study effect of individual drugs in AML patient samples as drugs
are mostly given in combinations.
Strong glucocorticoid sensitivity in a subset of AML patients with
wild-type FLT3
We analyzed glucocorticoid sensitivity data in 66 chemorefractory
samples from 48 individual AML patients. These samples include
18 samples from previously published study26 and 48 additional
new samples. Eleven of the AML samples (16%) with selective
DSSX 10 were considered strong responders to glucocorticoid
dexamethasone, whereas an additional 11 cases (32% together)
showed moderate sensitivity to dexamethasone with selective
DSS scores between 5 and 10 (Figure 5c). Sensitivity to
glucocorticoids showed strong correlation with each other in
AML patient samples, thus validating and conﬁrming the
observation (Supplementary Figure 4). We further explored
molecular proﬁling data from 29 relapsed and refractory AML
patient samples and observed that most of the strong dex-
amethasone responders carried wild-type Fms-Related Tyrosine
Kinase 3 (FLT3). In contrast, samples that harbored either FLT3
point mutations or ITD were completely non-responsive to
glucocorticoids (Figure 5d). Taken together, these ﬁndings suggest
the therapeutic potential of glucocorticoids in a FLT3 wild-type
subset of AML patients, resistant to cytarabine and standard
chemotherapy.
DISCUSSION
Here we tested 250 oncology drugs in cytarabine-resistant AML
cell models as well as in chemorefractory AML patient samples
ex vivo, and identiﬁed glucocorticoids as the drugs whose efﬁcacy
most consistently increased as resistance to cytarabine developed.
This was only seen in patients with wild-type FLT3.
Synthetic glucocorticoids are structurally similar33 immunomo-
dulatory agents mainly affecting cytokine production, cell cycle,
oncogene expression and apoptosis regulation.34,35 Although
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Figure 5. Enhanced efﬁcacy to glucocorticoids in chemorefractory AML patient samples revealed by ex vivo drug testing. (a, b) The DSS of
dexamethasone, methylprednisolone and prednisolone were compared between diagnostic and relapsed samples in 1064 and 1145 AML
patient cases using two-tailed student’s t-test. (c) The drug testing was performed with 66 relapsed and refractory samples from 48 AML
patients treated with cytarabine containing chemotherapy. The DSS of dexamethasone, methylprednisolone and prednisolone were
normalized against 15 healthy bone marrow samples and quantiﬁed as selective DSS. Each data point represents drug response from
individual patient sample. (d) Dexamethasone responses were compared between AML patient samples carrying FLT3 wild-type (n= 19) and
point and/or ITD mutation (n= 10) using Mann–Whitney U-test.
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therapeutic mechanisms and functions of glucocorticoids are well
known in ALL,36 it remain poorly understood in AML. Glucocorti-
coid mediated induction of apoptosis was reported in AML cell
lines.37 Methylprednisolone was shown to induce differentiation in
myeloid blasts in in vitro and in vivo AML cell models.38,39 Clinical
trials with chemotherapeutic agents and glucocorticoids resulted
in signiﬁcant response in a subset of AML patients suggesting
supportive role of glucocorticoids.40–42 However, dexamethasone
has shown to exert a cytoprotective effect when used in
combination with standard chemotherapy drugs and contributes
to chemotherapeutic resistance in ovarian cancer and in
glioblastoma.43,44 Therefore, glucocorticoids are known to exert
both synergistic and antagonistic effects with other cytotoxic
chemotherapeutic drugs across different cancer types.
Glucocorticoids induce apoptosis in leukemic cells through
binding to glucocorticoid receptor and subsequently to two major
transcription regulators NF-κB and AP-1.34,35 In our unbiased
approach using an integration of chemical biology and transcrip-
tomic proﬁling, expression of the glucocorticoid receptor NR3C1
showed a modestly but signiﬁcantly increased expression in the
cell line variants with increasing resistance to cytarabine. At the
protein level, this difference was more prominent. However, all
clinical samples expressing the NR3C1 did not show statistically
signiﬁcant association with the glucocorticoid responsiveness
using RNA-seq transcriptomics data. We did not ﬁnd gain or
ampliﬁcation of 5q31 region including NR3C1 in cytarabine-
resistant in vitro cells or clinical samples, which partially explains
no substantial increase of NR3C1 gene expression.
Even though glucocorticoids have been used in AML clinical
trials,40,41 their therapeutic potential in cytarabine-resistant
patients has not been previously described. Here we illustrate
enhanced glucocorticoid sensitivity in 16% of cytarabine treated,
relapsed or refractory patient samples. Although the patients
received combinatorial therapy containing cytarabine, the AML
cell line data suggest that cytarabine is alone sufﬁcient to cause
glucocorticoid sensitivity. Molecular proﬁling data further suggests
that wild-type FLT3 is signiﬁcantly associated with sensitivity to
glucocorticoids in chemorefractory AML patients. In fact, none of
the patients with FLT3-ITD or point mutations developed
glucocorticoid sensitivity. Paired samples from two patients
carrying wild-type FLT3 exhibited enhanced glucocorticoid sensi-
tivity after acquired cytarabine resistance. This ﬁnding is
consistent with enhanced sensitivity to glucocorticoids in SHI-1
cell line carrying wild-type FLT3, which was not observed in
MOLM-13 harboring FLT3-ITD. A study reported direct interaction
between FLT3 and dexamethasone to drive glucocorticoid
signaling pathway.45 We hypothesize that mutant and constitu-
tively active FLT3 changes glucocorticoid signaling-mediated
apoptosis in cytarabine-resistant AML cells.
Acquisition of cytarabine resistance leading co-resistance
to other nucleoside analogs corroborated with previous
observations.7,10 Although mutation and defective expression of
the DCK gene is known in leukemia and lymphomas,7–10,14,46 here,
we report focal homozygous deletion of DCK for the ﬁrst time in a
leukemia patient along with the conﬁrmation of nucleoside
analog co-resistance. Loss of DCK function in MOLM-13 and
SHI-1 cytarabine-resistant variants veriﬁes their validity with
previous studies.11,12 We observed no genetic changes or aberrant
expression in other genes previously reported to be involved
in cytarabine resistance, such as SLC29A1, CDA, NT5C2 and
NKG2D.12–14,17
In conclusion, acquisition of cytarabine resistance is associated
with an increase of glucocorticoid sensitivity in AML cell lines and
AML patient cells. Importantly, glucocorticoids present safer
treatment option compared with targeted drugs with toxic and
short-lived clinical responses in AML. Our results support the
concept that clinical studies are warranted to explore the effects
of glucocorticoids in chemorefractory AML patients carrying wild-
type FLT3.
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